Xiamen Amoytop Biotech | Sustainability Performance
Produces and supplies probiotics and microbial fermentation products.
1996
China
1,001 - 5,000 employees
Pharmaceuticals
$500M - 1B in revenue
$100M - 500M in profitability
Sustainability Ranking & Industry Benchmark
#9723
Overall#528
in China#235
in PharmaceuticalsSustainability Maturity
Sustainability Intent
Overview
Governance
TargetsESG scores and ExclusionsFinancial Data
Business performanceCapital & innovationAnalyst projections
Market cap
Revenue
R&D intensity
Controversy level
Powered by illuminem
Market cap
Revenue
EBITDA
Operating margin
P/E ratio
Revenue & EBITDA
$2.8BFY2024 revenue
Total Annual
Revenue & EBITDA
($ B)
Annual revenue
EBITDA
3 year change
Margin trends
Margin as % of revenue
Gross margin
Operating margin
Net margin
Powered by illuminem
Free cashflow
Capex
Debt/equity ratio
R&D intensity
10.2%FY2024
R&D as % of revenue
Return on invested capital (ROIC)
Industry benchmark
Powered by illuminem
Return on invested capital
32.0%FY2026
Return on invested capital (ROIC)
Industry benchmark
Powered by illuminem
Analyst revenue estimates & actuals
Analyst consensus vs actuals
($ B)
Actual revenue
Consensus estimates
Estimate only
1.5
▼ 5.2%
2.1
▼ 0.3%
2.8
▼ 1.5%
6.3
2027Powered by illuminem
Environmental policy coverage
Carbon reduction policy
Not available
Human rights policy
Not available
Recycling policy
Not available
Workplace health & safety policy
Not available
18%
Independent Directors
3 out of 17 incl. management
Overall score
0
Environment
0
Social
0
Governance
0
Exclusion screening
Adult content
Not available
Alcoholic
Not available
Animal testing
Not available
Firearms
Not available
Tobacco
Not available
Gambling
Not available
Nuclear
Not available
